March 31, 2014
Astellas Pharma’s sodium-glucose co-transporter-2 (SGLT-2) inhibitor Suglat (ipragliflozin) was the most promoted drug in the GP (99 beds or less) market in February, according to a survey conducted by a research firm. Suglat, which is anticipated to debut as Japan’s...read more